Cambridge biotech tracker

Cambridge biotech, by the numbers.

Cash, burn, runway, and audit-relevant flags for every listed biotech and pharma company headquartered in Cambridge and the Kendall-to-128 cluster, read directly from their SEC filings. The finance view of the neighborhood, refreshed each weekday.

Updated Sep 18, 2026Latest quarter Q2 '26Source: SEC EDGAR XBRL
Companies tracked
102
28 in Cambridge proper
Combined cash & investments
$64.3B
as of Q2 '26
Median runway
2.5 years
at the last four quarters' burn
Under 12 months of runway
20
37 under 24 months
Going-concern language
15
in a 10-Q or 10-K this cycle
Raised in the last four quarters
$18.9B
net financing cash flow

102 companies. Click a column to sort, a row for the full read.

CurisCRIS · Lexington · Q2 '26$5.1M2.0 mo
AgenusAGEN · Lexington · Q2 '26$18.7M2.3 mo
Seres TherapeuticsMCRB · Cambridge · Q2 '26$15.6M3.7 mo
Cue BiopharmaCUE · Boston · Q2 '26$17.4M4.2 mo
Transcode TherapeuticsRNAZ · Boston · Q2 '26$8.4M4.5 mo
Pyxis OncologyPYXS · Boston · Q2 '26$33.0M5.8 mo
Ernexa TherapeuticsERNA · Cambridge · Q2 '26$5.0M6.8 mo
BiofronteraBFRI · Woburn · Q2 '26$4.7M7.1 mo
Prime MedicinePRME · Cambridge · Q2 '26$95.1M7.3 mo
Elicio TherapeuticsELTX · Boston · Q2 '26$23.5M7.5 mo
iSpecimenISPC · Woburn · Q2 '26$4.4M7.6 mo
Neumora TherapeuticsNMRA · Watertown · Q2 '26$117M7.8 mo
Replimune GroupREPL · Woburn · Q2 '26$195M8.4 mo
ImmuneeringIMRX · Cambridge · Q2 '26$41.3M8.7 mo
Werewolf TherapeuticsHOWL · Waltham · Q2 '26$22.0M8.8 mo
MetaViaMTVA · Cambridge · Q2 '26$12.6M9.6 mo
VerastemVSTM · Needham · Q2 '26$136M10 mo
TScan TherapeuticsTCRX · Waltham · Q2 '26$100M10 mo
CervoMedCRVO · Boston · Q2 '26$24.9M11 mo
Karyopharm TherapeuticsKPTI · Newton · Q2 '26$65.1M12 mo
Acumen PharmaceuticalsABOS · Newton · Q2 '26$110M14 mo
Voyager TherapeuticsVYGR · Lexington · Q2 '26$149M15 mo
Adicet BioACET · Boston · Q2 '26$118M17 mo
Acrivon TherapeuticsACRV · Watertown · Q2 '26$90.0M17 mo
Atea PharmaceuticalsAVIR · Boston · Q2 '26$219M17 mo
Korsana BiosciencesKRSA · Waltham · Q2 '26$6.7M18 mo
Neuphoria TherapeuticsNEUP · Burlington · Q2 '26$19.9M19 mo
Entrada TherapeuticsTRDA · Boston · Q2 '26$223M20 mo
Scholar RockSRRK · Cambridge · Q2 '26$492M20 mo
PepGenPEPG · Boston · Q2 '26$117M20 mo
Ginkgo Bioworks HoldingsDNA · Boston · Q2 '26$302M21 mo
Intellia TherapeuticsNTLA · Cambridge · Q2 '26$628M22 mo
Dyne TherapeuticsDYN · Waltham · Q2 '26$898M23 mo
Generate BiomedicinesGENB · Somerville · Q2 '26$457M23 mo
Upstream BioUPB · Waltham · Q2 '26$261M23 mo
Amylyx PharmaceuticalsAMLX · Cambridge · Q2 '26$251M24 mo
Foghorn TherapeuticsFHTX · Cambridge · Q2 '26$168M24 mo
Solid BiosciencesSLDB · Charlestown · Q2 '26$378M24 mo
Aldeyra TherapeuticsALDX · Lexington · Q2 '26$45.1M25 mo
Stoke TherapeuticsSTOK · Bedford · Q2 '26$366M25 mo
Xilio TherapeuticsXLO · Waltham · Q2 '26$136M27 mo
Crescent BiopharmaCBIO · Waltham · Q2 '26$172M28 mo
Korro BioKRRO · Cambridge · Q2 '26$163M29 mo
X4 PharmaceuticalsXFOR · Boston · Q2 '26$208M30 mo
Ocular TherapeutixOCUL · Bedford · Q2 '26$599M30 mo
Cogent BiosciencesCOGT · Waltham · Q2 '26$792M31 mo
Agios PharmaceuticalsAGIO · Cambridge · Q2 '26$1.00B33 mo
Minerva NeurosciencesNERV · Burlington · Q2 '26$75.3M35 mo
Odyssey TherapeuticsODTX · Boston · Q2 '26$433M35 mo
Viridian Therapeutics, Inc.\DEVRDN · Waltham · Q2 '26$982M35 mo
Camp4 TherapeuticsCAMP · Watertown · Q2 '26$86.4M36 mo
Zenas BioPharmaZBIO · Waltham · Q2 '26$705M37 mo
Aura BiosciencesAURA · Boston · Q2 '26$324M38 mo
Tectonic TherapeuticTECX · Watertown · Q2 '26$227M38 mo
Rhythm PharmaceuticalsRYTM · Boston · Q2 '26$333M38 mo
Compass TherapeuticsCMPX · Boston · Q2 '26$180M38 mo
Editas MedicineEDIT · Cambridge · Q2 '26$393M39 mo
Vor BiopharmaVOR · Boston · Q2 '26$466M40 mo
Beam TherapeuticsBEAM · Cambridge · Q2 '26$1.20B40 mo
Mustang BioMBIO · Waltham · Q2 '26$15.2M40 mo
Black Diamond TherapeuticsBDTX · Cambridge · Q2 '26$111M40 mo
Sionna TherapeuticsSION · Waltham · Q2 '26$268M42 mo
C4 TherapeuticsCCCC · Watertown · Q2 '26$300M42 mo
Candel TherapeuticsCADL · Needham · Q2 '26$202M43 mo
Disc MedicineIRON · Watertown · Q2 '26$718M44 mo
Bicara TherapeuticsBCAX · Boston · Q2 '26$497M44 mo
Jade BiosciencesJBIO · Waltham · Q2 '26$461M45 mo
NuvalentNUVL · Cambridge · Q1 '26$1.29B49 mo
Relay TherapeuticsRLAY · Cambridge · Q2 '26$911M52 mo
Rapport TherapeuticsRAPP · Boston · Q2 '26$436M54 mo
Fulcrum TherapeuticsFULC · Cambridge · Q2 '26$319M58 mo
Q32 BioQTTB · Waltham · Q2 '26$106M60+ mo
Keros TherapeuticsKROS · Lexington · Q2 '26$258M60+ mo
Seaport TherapeuticsSPTX · Boston · Q2 '26$442M60+ mo
Praxis Precision MedicinesPRAX · Boston · Q2 '26$1.66B60+ mo
Spyre TherapeuticsSYRE · Waltham · Q2 '26$1.15B60+ mo
Avalyn PharmaAVLN · Boston · Q2 '26$540M60+ mo
Parabilis MedicinesPBLS · Cambridge · Q2 '26$1.12B60+ mo
Enanta PharmaceuticalsENTA · Watertown · Q2 '26$211M60+ mo
Kailera TherapeuticsKLRA · Waltham · Q2 '26$1.17B60+ mo
Hemab Therapeutics HoldingsCOAG · Cambridge · Q2 '26$457M60+ mo
Kymera TherapeuticsKYMR · Watertown · Q2 '26$1.50B60+ mo
ModernaMRNA · Cambridge · Q2 '26$6.91B60+ mo
Aktis OncologyAKTS · Boston · Q2 '26$517M60+ mo
Tango TherapeuticsTNGX · Boston · Q2 '26$1.01B60+ mo
Standard BiotoolsLAB · Boston · Q2 '26$795M60+ mo
Damora TherapeuticsDMRA · Waltham · Q2 '26$541M60+ mo
Monte Rosa TherapeuticsGLUE · Boston · Q2 '26$621M60+ mo
Akebia TherapeuticsAKBA · Cambridge · Q2 '26$156MSelf-funding
Alnylam PharmaceuticalsALNY · Cambridge · Q2 '26$3.31BSelf-funding
ApnimedAPMD · Cambridge · Q2 '26$173MSelf-funding
BiogenBIIB · Cambridge · Q1 '26$4.75BSelf-funding
Enveric BiosciencesENVB · Cambridge · Q2 '26
Ironwood PharmaceuticalsIRWD · Boston · Q2 '26$79.1MSelf-funding
Lantheus HoldingsLNTH · Bedford · Q2 '26$640MSelf-funding
Obsidian TherapeuticsOBX · Cambridge · Q2 '26$52.4MSelf-funding
RepligenRGEN · Waltham · Q2 '26$810MSelf-funding
Sarepta TherapeuticsSRPT · Cambridge · Q2 '26$934MSelf-funding
Spero TherapeuticsSPRO · Cambridge · Q2 '26$50.8MSelf-funding
VericelVCEL · Burlington · Q2 '26$227MSelf-funding
Vertex Pharmaceuticals IncVRTX · Boston · Q2 '26$13.6BSelf-funding
Zevra TherapeuticsZVRA · Boston · Q2 '26$260MSelf-funding

How to read this

Every number traces to a filing.

The tracker reads the XBRL data companies attach to their 10-Qs and 10-Ks. No estimates, no analyst models, no press releases. That also means it inherits whatever each company chose to tag.

Get this read for your company
Cash & investments
Cash and cash equivalents plus marketable securities, current and long-term, at the latest balance-sheet date. Where a company only tags the combined total, that is used. A few small companies tag only cash.
Burn per quarter
Average operating cash outflow over the last four reported quarters, from the cash flow statement. Quarterly figures are derived from the year-to-date amounts in 10-Qs. This excludes financing and investing flows, so a raise or a debt draw does not flatter it.
Runway
Cash and investments divided by quarterly burn, times three. Self-funding means operating cash flow was positive on average. Companies plan against their own budgets, so treat this as the outside view, not their guidance.
Net loss and R&D
The latest three-month figures. Fourth quarters are derived from the annual number minus the nine-month year-to-date. Net loss includes non-cash items like stock compensation, which is why it usually exceeds burn.
Raised, four quarters
Net cash from financing activities over the last four quarters: equity raises, debt, ATM sales, less repayments and buybacks.
Filing flags
Going concern means the latest 10-Q or 10-K contains definite substantial-doubt language, the kind that comes from an ASC 205-40 evaluation rather than a risk-factor hypothetical. Material weakness means the filing states one was identified. Both are found by full-text search of EDGAR, so read the filing before drawing conclusions.
Who is included
Companies with a business address in Cambridge, Boston, Somerville, Watertown, Waltham, Lexington, Bedford, Burlington, Woburn, Newton, Needham, or Charlestown, an SEC industry code for pharmaceutical preparations, biological products, diagnostics, or commercial biological research, a listed ticker, and a periodic filing in the last fifteen months. The list is re-derived from EDGAR weekly.
What this is not
Not investment advice, not audited by me, and not a substitute for reading the filing. Companies restate, retag, and file late. If a number looks off, the filing wins and I would like to hear about it.